Delivery Order SPE2DB20D2104-SPE2DB25FMWMB
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product for immunological treatment. The contract is a firm fixed price delivery order with no set-aside designation, awarded on July 24, 2025, with an ultimate completion date of July 25, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, performed this work at its corporate office location. This delivery order...
- The Defense Logistics Agency awarded a $41,926.99 firm fixed price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls pharmaceutical supply. This non-competitive delivery order, awarded on August 13, 2025, with an ultimate completion date of August 14, 2025, represents a child contract under AmerisourceBergen's larger federal pharmaceutical supply vehicle. The product will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $2,939.30 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product for treating inflammatory conditions. The contract employs firm fixed pricing and was awarded on August 1, 2025, with an ultimate completion date of August 4, 2025. This delivery order represents a non-competitive procurement issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mL on August 5, 2025, with an ultimate completion date of August 6, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is the place of performance for this contract. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $34,594.70 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on July 28, 2025, with a completion date of July 29, 2025. This non-competitive, firm fixed-price delivery order represents a fulfillment under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a total value of $999,999,999.00 through December 2026. The product will be delivered to...
- The Defense Logistics Agency issued a delivery order worth $4,145.88 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used in the treatment of inflammatory conditions. This firm fixed-price delivery order, awarded on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a non-competitive award under the company's larger contract vehicle with DLA. The product will be delivered to AmerisourceBergen's facility in Conshohocken,...
- The Defense Logistics Agency awarded a $4,849.35 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls pharmaceutical supply, with an ultimate completion date of August 12, 2025. This non-set-aside competitive award was issued on August 11, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a...
- The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract valued at $3,694.32 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, a leading global pharmaceutical distributor. The contract is for the supply of HUMIRA (CF) PEN 40 MG/0.4 MLS, a specialty pharmaceutical product. The firm fixed price delivery order has a completion date of March 20, 2024. AmerisourceBergen Drug Corp is the prime contractor and does not have any major subcontractors listed....
- The U.S. Department of Defense's Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order worth $1,385.37 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The delivery order is for HUMIRA PEN 40 MG/0.8 MLS, a specialty pharmaceutical product. This order is part of a larger $999,999,999.00 indefinite delivery contract (IDC) awarded to Amerisourcebergen Drug Corp to provide a comprehensive range of pharmaceutical products and...
- The Defense Logistics Agency awarded a delivery order valued at $5,543.70 to AmerisourceBergen Drug Corp for the supply of Humira Pen 40 mg/0.8 mls, a pharmaceutical product used to treat inflammatory conditions. This competitively awarded, firm fixed-price contract was issued on July 22, 2025, with an ultimate completion date of July 23, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMWMBDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,741.71 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL pharmaceutical supplies. The contract is a firm fixed price delivery order with an ultimate completion date of July 28, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX, valued at $999,999,999.00 and running through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly serving military and veteran healthcare systems through the DLA Medical Supply Chain. The company's federal contract portfolio demonstrates extensive capabilities in supplying brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. All reviewed contract awards indicate the company's ability to meet federal procurement requirements through open competition, with pricing arrangements ranging from small-value transactions to substantial orders, positioning AmerisourceBergen as a versatile partner for supporting defense and healthcare system pharmaceutical needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.7k | 7/25/25 |